IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

Comment on: Lancet Diabetes Endocrinol. 2014 May;2(5):369-84. doi: 10.1016/S2213-8587(13)70208-0. Epub 2014 Jan 24. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG RENAL trial investigators.

Dreaming of normoglycaemia with fewer diet restrictions / P. Ruggenenti, G. Remuzzi. - In: THE LANCET DIABETES & ENDOCRINOLOGY. - ISSN 2213-8587. - 2:5(2014 May), pp. 350-351. [10.1016/S2213-8587(14)70002-6]

Dreaming of normoglycaemia with fewer diet restrictions

G. Remuzzi
Ultimo
2014

Abstract

Comment on: Lancet Diabetes Endocrinol. 2014 May;2(5):369-84. doi: 10.1016/S2213-8587(13)70208-0. Epub 2014 Jan 24. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG RENAL trial investigators.
Endocrinology; Diabetes and Metabolism; Internal Medicine; Endocrinology; Medicine (all)
Settore MED/14 - Nefrologia
mag-2014
Article (author)
01 - Articolo su periodico
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/330141
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact